Polsinelli Represents NewLeaf Symbiotics, Inc. in $45 Million Series D Financing

Polsinelli congratulates its client NewLeaf Symbiotics, Inc., on its $45 million Series D financing. NewLeaf is a pioneer and global leader of pink-pigmented facultative methylotrophs (PPFMs), which are naturally occurring microbes that help plants reach their full genetic potential.

The financing was led by Gullspång Re:food and followed by Otter Capital Partners LP, S2G Ventures, and Leaps by Bayer, among others. The financing will help accelerate NewLeaf’s efforts with PPFM technology and adjacent technologies in the areas of biostimulants/microbial inoculants, biocontrol, nitrogen use efficiency and methane mitigation.

The Polsinelli Venture Capital and Emerging Growth Companies team involved in the transaction included Brendan Johnson, Laura Venn, Garrett McDowell and Sugeiry Betances.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 1,000 attorneys in 23 offices nationwide. Recognized by legal research firm BTI Consulting as one of the top firms for excellent client service and client relationships, Polsinelli is committed to meeting our clients’ expectations of what a law firm should be. Our attorneys provide value through practical legal counsel infused with business insight with a focus on health care, real estate, finance, technology, private equity, and corporate transactions. Polsinelli LLP in California, Polsinelli PC (Inc) in Florida.